Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-15
2008-01-15
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S324000, C514S374000, C514S331000, C514S365000, C544S323000, C548S187000, C548S235000
Reexamination Certificate
active
10505333
ABSTRACT:
Compounds of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof, are disclosed. Methods of making and using the compounds are also disclosed. In particular methods for treating diseases or conditions associated with one or more of human PPAR alpha, gamma, or delta (“hPPARs”) comprising administration of a therapeutically effective amount of a compound of formula (1), are disclosed
REFERENCES:
patent: 4214094 (1980-07-01), Kamiya et al.
patent: 5935985 (1999-08-01), Hamanaka et al.
patent: WO97/25042 (1997-07-01), None
patent: WO 01/00603 (2001-01-01), None
patent: WO 01/40207 (2001-06-01), None
patent: WO 02/46176 (2002-06-01), None
Hcaplus 134:125379.
Thiemermann, C., “Ligands of the peroxisome proliferator-activated receptor- y and heart failure”, British Journal of Pharmacology (2004) 141 (1), 1-3.
Schriffin, Ernesto, “Peroxisome proliferator-activated receptors and cardiovascular remodeling”, American Journal of Physiology—Heart and Circulatory Physiology 288:1037-1043, 2005.
Brown, Peter J., et al. “Generation of secondary alkyl amines on solid support by borane reduction. Application to the parallel synthesis of PPAR ligands.” Synthesis (1997), (7), pp. 778-782.
Wilson, T.M., et al. “The PPARS: From Orphan Receptors to Drug Discovery.” Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 43, No. 4., pp. 530, 540.
Lewis, D.F.V., et al. “Molecular modeling of the rat peroxisome proliferators-activated receptor -alpha (rPPARalpha) by homology with the human retinoic acid X receptor alpha (hRXRalpha) and investigation of ligand binding interactions I: QSARs.” Toxicology In Vitro, Elsevier Science, GB, vol. 12, No. 6, Dec. 1998 pp. 619-632.
Brown, P.J., et al. “Identification of Peroxisome Proliferator-Activated Receptor Ligands from a Biased Chemical Library.” Chemistry and Biology, Currently Biology, London, GB., vol. 4, No. 12, Dec. 1997, p. 910.
Brown, P.J. et al. “Identification of a Subtype Selective Human PPARalpha Agonist Through Parallel-Array Synthesis.” Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 11, Mar. 12, 2001, pp. 1225-1227.
Liu, Kevin G., et al. “Identification of a Series of PPAR.gamma./.delta. dual agonists via solid-Phase parallel synthesis.” Bioorganic & Medicinal Chemistry Letters, 2001, 11(22), pp. 2959-2962.
Cadilla Rodolfo
Henke Brad Richard
Lambert, III Millard H.
Liu Guangcheng Kevin
Smith Jennifer Susan
Andres Janet L.
Fox Jennifer L.
Robinson Binta
SmithKline Beecham Corporation
LandOfFree
hPPARs activators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with hPPARs activators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and hPPARs activators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3928449